<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Present study was carried out to investigate the possible neuroprotective effect of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, an <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agent, peroxisome proliferator-activated receptor gamma (PPARgamma) <z:chebi fb="4" ids="48705">agonist</z:chebi> on <z:hpo ids='HP_0011009'>acute</z:hpo> phase changes in mice model of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> induced by Bilateral Common Carotid <z:mp ids='MP_0006134'>artery Occlusion</z:mp> (BCCAO) </plain></SENT>
<SENT sid="1" pm="."><plain>BCCAO model was used to induce partial global <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>BCCAO induced significant brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:hpo ids='HP_0000969'>edema</z:hpo> in saline treated control group along with high increase in <z:mp ids='MP_0003674'>oxidative stress</z:mp> showed by increase <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation and decreased levels of <z:chebi fb="11" ids="22586">antioxidants</z:chebi> like <z:chebi fb="1" ids="18421">superoxide</z:chebi> <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutage, catalase, <z:chebi fb="0" ids="16856">glutathione</z:chebi> peroxidase </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> (20 mg/kg, orally) administration showed neuroprotective effects by reducing cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> size significantly as compared to control group </plain></SENT>
<SENT sid="4" pm="."><plain>Postischemic <z:hpo ids='HP_0001250'>seizure</z:hpo> susceptibility was also reduced as number of positive responders decreased to a significant number </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0002181'>Brain edema</z:hpo> was subsided to a significant level </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> reduced the plasma TNF-alpha levels as compared to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> group significantly </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> treatment also improved <z:hpo ids='HP_0000001'>all</z:hpo> the <z:chebi fb="11" ids="22586">antioxidants</z:chebi> levels showing activity against <z:mp ids='MP_0003674'>oxidative stress</z:mp> induced by BCCAO </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> showed neuroprotection against ischemic insult suggesting the role of PPARgamma <z:chebi fb="4" ids="48705">agonist</z:chebi> in neuroprotective agents </plain></SENT>
</text></document>